Olaplex
The receipt the consumer is now asking for
In this issue
The Quarter in Brand Authority
Brand Authority Watch — Olaplex
The Vocabulary Shift
On February 10, [Circana] released US beauty full-year 2025 results. Prestige closed at $36 billion, up 4 percent. Mass reached $72.7 billion, up 5 percent. All pillar categories in prestige grew on all metrics for the full year. Hair led prestige. Fragrance normalized to 5 percent after two consecutive years of double-digit growth. Makeup remained the largest prestige category.
The number the trade is not reading correctly is the average selling price. Prestige ASP was up 1 percent in 2025, the smallest ASP increase since 2021. For three years after the pandemic, prestige growth was partly a pricing story: the consumer was paying more per unit, and that price increase was masking flat or declining unit volumes in some segments. In 2025, the pricing lever produced only 1 percent of the 4 percent growth. The remaining 3 percent came from unit growth. That is a structurally healthier number than the prior three years, but it is also a signal that the pricing power that premium brands assumed they had is narrowing.
The brand authority consequence is specific. A brand that has been growing revenue by taking price without building corresponding proof of value is now in a more exposed position than it was in 2022 or 2023. The consumer who was absorbing price increases because prestige beauty felt like an accessible luxury is now doing more research before she spends. [Kearney]’s February 2026 consumer survey confirmed it directly: nearly half of respondents ranked efficacy and value as their top purchase drivers, fewer than a quarter care about legacy, and more than half actively swap premium products for alternatives they believe work just as well.
The brands that grew unit volume in 2025, not just revenue, are the ones with proof architectures the consumer has decided are worth paying for. The brands that needed price increases to sustain revenue growth are the ones that will face the hardest test in 2026 as the consumer becomes more selective and the pricing environment becomes less forgiving.
For the subscriber: the 1 percent ASP increase is not a reassuring sign. It is a narrowing window. The brands that build verifiable proof of value now, a named mechanism, a documented outcome, a specific and traceable reason the product works, are building the authority position that holds when pricing power contracts. The brands that are still growing primarily through aesthetics and lifestyle positioning are operating on borrowed time in a market that is beginning to demand a receipt.
Olaplex holds the most dramatic proof gap in the tracked field. Bis-aminopropyl diglycol dimaleate is a category-creating patent. It created the bond-building segment of professional hair care. Peer-reviewed. No category equivalent at launch. The mechanism is a 10 by any proof architecture standard.
In early January 2026, Bloomberg reported that Henkel had submitted a takeover offer for Olaplex and that the two were in discussions about a deal that could materialize within weeks. Through February, those discussions were active and public. The acquisition was confirmed on March 26: $1.4 billion, a 55 percent premium over Olaplex’s closing price. [WWD] The stock had lost more than 90 percent of its value since its 2021 IPO. [Retail Dive]
The gap between those two numbers is the Olaplex diagnosis in its most concentrated form. A $1.4 billion acquisition premium on a brand whose stock had fallen to $1.33 per share. Henkel paid for the patent, the professional channel relationship, and the brand name. The market price reflected what the ‘Designed to Defy’ rebrand had communicated to public equity investors over the prior three years: a brand that had abandoned the mechanism that created its category in favor of an emotional register that the market did not believe.
The patent did not change. The professional channel was rebuilding: 5.5 percent growth in 2025. What changed was the communication. And what the acquisition confirms is the gap between the patent’s actual value and the market’s assessment of the brand’s communication of it. Henkel is paying $1.4 billion for what the public market was valuing at under $1 per share. The difference is the communication gap made quantifiable.
For the subscriber: the Olaplex acquisition is the clearest financial proof the Brief has encountered of what a communication gap costs. The brand with the category-creating patent traded at $0.99 per share at its lowest. The acquirer who understood what the patent was worth paid a 55 percent premium to take it private. The consumer who bought Olaplex No. 3 at its peak understood intuitively what the mechanism did. The investor who sold at $0.99 did not, because the brand had spent three years telling a different story. The patent was always a 10. The communication of it was a 5. The distance between those two numbers produced a $1.4 billion acquisition opportunity for a company that could read the gap.
The diagnostic question this Brief will now track under Henkel ownership: does a conglomerate that owns Got2b, Joico, Kenra, and Schwarzkopf communicate a bond-building patent with more or less specificity than the brand’s own management team did under public market pressure? The professional channel is the answer key. If the salon relationship rebuilds, the mechanism will have found its communication again. If the consumer brand moves further into the Henkel mass-market aesthetic, the patent will have been acquired for distribution rather than authority.
Status: Crossing from trade to consumer vocabulary
"Proof" has been mainstream in trade press and brand communication since Q4 2024, when The Undercurrent first tracked it entering category vocabulary. In February 2026 it is crossing a different threshold: it is moving from language that brands use to describe their products into language that consumers use to evaluate them.
The [Kearney] survey published February 24 is the evidence. More than 80 percent of shoppers are now swayed by scientific proof, clinical validation, and biotech: the consumer’s own language, not the brand’s. That shift is structurally significant. When "proof" was trade vocabulary, a brand could adopt it without having to deliver it. When it becomes consumer vocabulary, the consumer is arriving at the shelf with a specific expectation: show me the proof.
The authority implication is the sharpest it has been since this Brief began tracking the term. A brand that adopted "proof" language in 2024 and 2025 without a named mechanism beneath it is now communicating in a language the consumer is actively interrogating. The consumer who has been educated by two years of clinical brand launches, Augustinus Bader, K18, Olaplex at its peak, has a framework for what proof looks like. A brand that uses the vocabulary without the substance is no longer just missing a trend. It is failing a consumer test.
For brands that have the proof: February 2026 is the moment to name it more specifically, not less. The consumer is ready for the mechanism. She is not just ready for "clinically proven." She is ready for "TFC8" and "K18Peptide" and "bis-aminopropyl diglycol dimaleate." The brands that have been translating their proof into accessible language have an opportunity to take one step back toward the specificity. The consumer has caught up.